Immunovant, Inc. Common Stock | IMVT

Daily Technical Analysis of Immunovant, Inc. Common Stock

Immunovant had a nice pop today and is currently up 3.77% we'll see if the cash keeps flowing in.

It looks like Immunovant isn't currently at a very decisive point in regards to support/resistance levels. Momentum wise Immunovant, has been oscillating up and down but hasn't shown much directional energy that would be predictive to the near future. IMVT might find some support at the 14.2 level, buyers might push the price back up from here. But it's not very clear what will happen.

Analyst Ratings for Immunovant By Price Target And Rating

The analysts feel fairly neutral on the prospects for Immunovant but a little more positive than negative. The current Analysts Sentiment Score is 34.29. Most companies range between (-200 to 200).

Here's a break down of the latest rating changes. Oppenheimer initiated a rating of Outperform on 2024-03-28 and added a price target of $50.00. On 2024-03-25 there was confirmation of the previous rating by Truist Financial which was Buy and added a price target of $48.00. The Goldman Sachs Group initiated a rating of Buy on 2024-03-13 and provided a price target of $50.00. JPMorgan Chase & Co. announced that they are initiating coverage with a rating of Overweight on 2024-02-20 and they set their price target at $51.00.On 2024-02-15 Wolfe Research started covering Immunovant with a rating of Outperform and added a price target of $55.00. Cantor Fitzgerald announced that they are reiterating a rating of Overweight on 2024-01-12. HC Wainwright gave a boost to their price target and moved to $51.00 from $47.00 on 2023-12-21. Bank of America gave a boost to their price target and moved to $51.00 from $49.00 on 2023-12-21. On 2023-12-12 Deutsche Bank Aktiengesel started covering Immunovant with a rating of Buy and added a price target of $50.00. On 2023-12-01 UBS Group increased their price target by 1.82% to $56.00.

Earnings Per Share (EPS) Estimates By Year and Quarter

Short interest for Immunovant

We take into account several different measures of short interest to create a composite score. These measures are shown in the chart below. Short selling is when investors are betting against a stock. We compile these factors to create a dynamic Short Score - this can indicate poor sentiment, internal problems with a company or industry and the anticipation of future price declines. We look at the short interest percent, days to cover, the rate of change and total shares sold short.

Social Sentiment for Immunovant

Social Sentiment is an aggregation of several different factors such as news, articles, blogs, user content, ratings, etc. Which is shown in the chart below. It may become predictive of a reversal if price and the sentiment diverge. Broader market forces may push prices up or down but if market participants maintain a different view on a specific stock, it may be taken as an opportunity to buy or sell in those cases.